Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Add To Watchlist

Recent & Breaking News (PINL:VBIVQ)

VBI Vaccines Partners with the Utah CMV Council to Raise CMV Awareness

GlobeNewswire February 12, 2015

VBI Vaccines Partners with Le Classique to Raise CMV Awareness in Canada

GlobeNewswire January 8, 2015

VBI Vaccines to Present at the Noble Financial Capital Markets Equity Conference

GlobeNewswire January 6, 2015

LifeSci Capital Initiates Coverage of VBI Vaccines

Accesswire December 17, 2014

VBI to Present at the Equities.com Small-Cap Stars Conference

GlobeNewswire December 9, 2014

Andrews & Springer LLC Has Filed a Class Action Lawsuit on Behalf of Legacy Shareholders of VBI Vaccines, Inc. (f/k/a Paulson Capital Corp.) - VBIV

GlobeNewswire November 26, 2014

VBI to Present at the LD Micro Conference

GlobeNewswire November 24, 2014

VBI Reports Third Quarter 2014 Financial Results and Provides Update on CMV Vaccine Development

GlobeNewswire November 14, 2014

VBI to Present at the CMV Public Health & Policy Conference

GlobeNewswire September 24, 2014

New Data Supporting VBI's Prophylactic Cytomegalovirus (CMV) Vaccine Candidate (VBI-1501A) Presented at the 54th ICAAC Conference in Washington, D.C.

GlobeNewswire September 15, 2014

Variation Biotechnologies and Paulson Capital Announce Completion of Merger

GlobeNewswire July 28, 2014

Paulson Capital Announces Stockholder Approval of Contemplated Merger With Variation Biotechnologies (US)

GlobeNewswire July 15, 2014

Paulson Capital (Delaware) Corp. Announces Meeting Date and Record Date for the Special Meeting of Stockholders

GlobeNewswire June 24, 2014

Paulson Capital and Variation Biotechnologies Enter Into Merger Agreement

GlobeNewswire May 9, 2014

Paulson Capital Corp. to Remain Listed on NASDAQ; Receives Letter of Reprimand

GlobeNewswire February 20, 2014

Paulson Capital Corp. Announces Changes to Its Board of Directors

Globe Newswire January 28, 2014

NASDAQ Scheduled Resumption in Paulson Capital Corporation

Globe Newswire January 7, 2014

Paulson Capital Corp. Announces Shares to Resume Trading Pending Hearing Disposition; Issuance of and Intention to Appeal NASDAQ Determination Letter; and Appointment of Independent Director

Globe Newswire January 6, 2014

NASDAQ Halts Paulson Capital Corporation

Globe Newswire November 20, 2013

Paulson Capital Corp. Announces Meeting Date and Record Date for the 2013 Annual Meeting of Shareholders

Globe Newswire September 27, 2013